Frontier Science & Technology Research Foundation, Inc.
11
2
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
2 terminated/withdrawn out of 11 trials
50.0%
-36.5% vs industry average
18%
2 trials in Phase 3/4
200%
4 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV
Role: collaborator
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Role: collaborator
Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies
Role: collaborator
Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda
Role: collaborator
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Role: collaborator
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Role: collaborator
Long-Term Outcomes of Children With Congenital CMV in New York State
Role: collaborator
A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Role: collaborator
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Role: collaborator
Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome
Role: collaborator
Novel Treatment Option for Neuropathic Pain
Role: collaborator
All 11 trials loaded